Live feed
Filing
SCHEDULE 13G
SCHEDULE 13G0000932471-25-000763·Amylyx Pharmaceuticals, Inc.
Schedule 13G ownership disclosure
Amylyx Pharmaceuticals Inc
Common Stock · CUSIP: 03237H101
Event date: 2025-06-30
- Filing-level shares
- 4,498,028
- Percent of class
- 5.04%
- The Vanguard Group
Shares: 4,498,028 · Class: 5.04%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000932471-25-000763
- Form type
- SCHEDULE 13G
- Filer
- Amylyx Pharmaceuticals, Inc.
- CIK
- CIK 1658551
- Filed
- Jul 29, 2025
- Reporting period
- Jun 30, 2025
- Description
- Schedule 13G beneficial ownership